- Home
- MLSS vs LPTX Comparison
MLSS vs LPTX Comparison
Compare MLSS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- LPTX
- Stock Information
- Founded
- MLSS 1989
- LPTX 2011
- Country
- MLSS United States
- LPTX United States
- Employees
- MLSS N/A
- LPTX N/A
- Industry
- MLSS Industrial Specialties
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLSS Health Care
- LPTX Health Care
- Exchange
- MLSS Nasdaq
- LPTX Nasdaq
- Market Cap
- MLSS 42.4M
- LPTX 35.4M
- IPO Year
- MLSS 1995
- LPTX N/A
- Fundamental
- Price
- MLSS $0.43
- LPTX $0.46
- Analyst Decision
- MLSS Buy
- LPTX Hold
- Analyst Count
- MLSS 1
- LPTX 1
- Target Price
- MLSS $1.25
- LPTX N/A
- AVG Volume (30 Days)
- MLSS 184.8K
- LPTX 8.0M
- Earning Date
- MLSS 11-13-2025
- LPTX 11-12-2025
- Dividend Yield
- MLSS N/A
- LPTX N/A
- EPS Growth
- MLSS N/A
- LPTX N/A
- EPS
- MLSS N/A
- LPTX N/A
- Revenue
- MLSS $9,083,205.00
- LPTX N/A
- Revenue This Year
- MLSS $16.06
- LPTX N/A
- Revenue Next Year
- MLSS $14.73
- LPTX N/A
- P/E Ratio
- MLSS N/A
- LPTX N/A
- Revenue Growth
- MLSS 7.84
- LPTX N/A
- 52 Week Low
- MLSS $0.38
- LPTX $0.22
- 52 Week High
- MLSS $1.39
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MLSS 34.39
- LPTX 46.38
- Support Level
- MLSS $0.43
- LPTX $0.43
- Resistance Level
- MLSS $0.46
- LPTX $0.66
- Average True Range (ATR)
- MLSS 0.04
- LPTX 0.09
- MACD
- MLSS -0.00
- LPTX -0.03
- Stochastic Oscillator
- MLSS 0.69
- LPTX 4.86
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.